Epidermal growth factor receptor 3 (ERBB3)

Epidermal growth factor receptor 3—more commonly referred to by its gene name ERBB3 or HER3—is a member of the ErbB/HER family of receptor tyrosine kinases. Unlike some other members such as EGFR (HER1) and HER2, ERBB3 has impaired intrinsic kinase activity but plays a critical role in cellular signaling through heterodimerization with other ErbB receptors, especially HER2. This interaction activates downstream pathways involved in cell proliferation, survival, differentiation, and migration. ERBB3 is implicated in various cancers where it contributes to tumor progression and therapy resistance through its ability to activate potent pro-survival signals when paired with active partners like HER2. It is considered an important therapeutic target under investigation for novel anti-cancer strategies focused on disrupting these oncogenic interactions. Note: The search results provided information about "fibroblast growth factor receptor 3" (FGFR‑3) rather than "epidermal growth factor receptor 3." There is no widely recognized entity called "epidermal growth factor receptor 3"—the correct nomenclature should be ErbB‑family member  HER (ErbB) receptors, specifically ErbB‑1 (EGFR/HER1), ErbB‑2 (HER2), ErbB‑4 (HER4)—and what would be called “epidermal growth factor receptor  three” corresponds instead to ErbB‑three, also known as HER three. Therefore: is_incorrect: true — The term “epidermal growth factor receptor three” is not standard; the correct canonical name should be “Receptor tyrosine-protein kinase erb B‐three” (ERBB three, also known as HER three) rather than “Epidermal growth factor receptor three.”

Other names

ErbB-3HER3Receptor tyrosine-protein kinase erbB-3

Drugs targeting this molecule typically act by inhibiting ligand binding, blocking dimerization with other ErbB receptors (especially HER2), or interfering with downstream signaling pathways such as PI3K/AKT.